Asp38Ala与Thr59Lys家族性转甲状腺素蛋白淀粉样变性的眼部表现
该观察性病例系列前瞻性收集了16例因轻度周围神经病变接受tafamidis治疗的家庭性转甲状腺素蛋白淀粉样变性(FTA)患者的眼科检查数据,其中6例出现眼部受累。研究首次描述了Asp38Ala和Thr59Lys两种突变类型可表现为前囊膜混浊和视网膜沉积物等眼部体征。
要点
- Asp38Ala和Thr59Lys突变型FTA可出现前囊膜混浊和视网膜沉积物等眼部表现。
- Glu89Lys突变患者可见视网膜沉积物、视网膜出血和角膜混浊。
- OCTA可检测淀粉样沉积物血管周围袖套样改变所致血流减少。
核心结论
- Asp38Ala和Thr59Lys两种转甲状腺素蛋白突变型FTA可表现出前囊膜混浊和视网膜沉积物等眼部体征。
研究设计与样本
- 观察性病例系列,前瞻性收集2013年1月至2020年3月单中心16例因轻度周围神经病变接受tafamidis治疗的FTA患者的综合眼科检查数据。
主要发现
- 16例FTA患者中6例出现眼部受累。
- 3例Glu89Lys突变患者中2例出现视网膜沉积物、视网膜出血和角膜混浊。
- 9例Asp38Ala突变患者中3例和2例Thr59Lys突变患者中1例出现眼部受累,此前未见描述。
- 眼部表现包括青光眼、前囊膜混浊、玻璃体混浊和视网膜沉积物。
- OCTA检测到淀粉样沉积物血管周围袖套样改变所致血流减少。
临床怎么用
- 对Asp38Ala和Thr59Lys突变型FTA患者应进行眼科筛查以发现潜在眼部受累。
- OCTA可用于评估FTA患者视网膜血流改变。
局限性
- 样本量小(16例),为单中心观察性病例系列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the ophthalmic manifestations of familial transthyretin amyloidosis (FTA) mutations, including Asp38Ala and Thr59Lys, which have not been previously reported to have ocular involvement. METHODS: This is an observational case series of prospectively collected data of 16 patients with FTA who were taking tafamidis for mild peripheral neuropathy and underwent a comprehensive ophthalmic examination at a single tertiary center, between January 2013 and March 2020. The ocular involvement of each FTA mutation type and the specific manifestations were the main outcome measures. RESULTS: Six of 16 patients with FTA manifested ocular involvement. Ocular involvement was noted in two of three patients with Glu89Lys mutations having retinal deposits, retinal hemorrhages, and corneal opacity. Three of nine patients with Asp38Ala mutations and one of two patients with Thr59Lys mutations showed ocular involvement that had not been previously described. The ophthalmic findings included glaucoma, anterior lens capsule opacity, vitreous opacity, and retinal deposits. The decrease in vascular flow due to perivascular cuffing of the amyloid deposits was detected by optical coherence tomography angiography. CONCLUSION: The current study newly described that two transthyretin mutation types of FTA, Asp38Ala and Thr59Lys, may manifest with ocular findings such as anterior lens capsule opacity and retinal deposits.
引用
- Choi KJ, Son KY, Kang SW, et al. OCULAR MANIFESTATIONS OF ASP38ALA AND THR59LYS FAMILIAL TRANSTHYRETIN AMYLOIDOSIS. Retina. 2022. PMID: 34483316. doi:10.1097/IAE.0000000000003296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。